Earnings Call Insights: MNTN, Inc. (MNTN) Q1 2026 Management View Mark Douglas (Founder, President, CEO & Chairman of the Board) said the quarter delivered “first quarter revenue growth of 25% year-over-year, along with strong adjusted EBITDA growth of 74% year-over-year and record positive net income,” while reiterating MNTN’s focus on “democratiz[ing] television advertising” for performance mark...
Earnings Call Insights: MNTN, Inc. (MNTN) Q1 2026 Management View Mark Douglas (Founder, President, CEO & Chairman of the Board) said the quarter delivered “first quarter revenue growth of 25% year-over-year, along with strong adjusted EBITDA growth of 74% year-over-year and record positive net income,” while reiterating MNTN’s focus on “democratiz[ing] television advertising” for performance marketers in Connected TV. Mark Douglas (Founder, President, CEO & Chairman of the Board) announced product and go-to-market updates centered on AI and creative, saying, “QuickFrame AI, our AI-powered creative video platform was released from beta this morning and has become one of the fastest-growing elements in the Mountain suite,” and that “QuickFrame AI 3.0 brings a major expansion of capabilities,” including “a new storyboard editor” and “collaborative editing.” Mark Douglas (Founder, President, CEO & Chairman of the Board) highlighted senior hires tied to scaling revenue and inventory access: “the addition of Garland Hill as Mountain's Chief Revenue Officer; and Peter Blacker as Head of Content,” adding that Peter’s remit is “to ensure Mountain provides our customers access to nearly all of that content.” Patrick Pohlen (Chief Financial Officer) said, “We reported strong first quarter results to start the year, exceeding our prior revenue and adjusted EBITDA guidance,” and added, “Although we are committed to gradually delivering operating leverage, our primary focus is on pursuing strong growth rather than maximizing our margins.” Outlook Patrick Pohlen (Chief Financial Officer) guided Q2 2026 revenue to “the range of $81 million and $83 million” and adjusted EBITDA to “between $19 million and $22 million.” Patrick Pohlen (Chief Financial Officer) raised full-year 2026 revenue guidance to “the range of $347 million and $357 million” and guided full-year adjusted EBITDA to “between $96 million and $101 million.” Compared with the prior quarter’s call, management increased...
Earnings Call Insights: Arista Networks (ANET) Q1 2026 Management View “Arista has experienced significant velocity in all our sectors in Q1 and are now commanding the #1 market share in high-speed switching in the greater than 10 gigabit Ethernet category,” said CEO & Chairperson Jayshree Ullal. Ullal framed AI networking around “3 AI fabric use cases” and added, “Scale-Up will be a new entry for...
Earnings Call Insights: Arista Networks (ANET) Q1 2026 Management View “Arista has experienced significant velocity in all our sectors in Q1 and are now commanding the #1 market share in high-speed switching in the greater than 10 gigabit Ethernet category,” said CEO & Chairperson Jayshree Ullal. Ullal framed AI networking around “3 AI fabric use cases” and added, “Scale-Up will be a new entry for Arista in 2027 and beyond,” while also saying Arista has “greater than 100 cumulative customers to date in 800 gigabit Ethernet deployments” and “expect the addition of 1.6 terabit in 2027 at production scale.” Ullal highlighted the supply-demand backdrop and its margin implications: “We are experiencing industry-wide shortages across the board,” adding, “We anticipate gross margin pressure due to mix and trade-offs we are making to pay more to assure supply continuity to our customers.” Senior VP & CFO Chantelle Breithaupt said, “total revenues in Q1 were $2.71 billion,” and added, “Overall, this resulted in net income for the quarter of $1.11 billion.” Outlook Ullal said supply constraints are expected to persist: “We now think it’s a 1- or 2-year phenomena,” and added, “we are going to do everything, including hurt our gross margins to supply to that demand this year and next year.” Breithaupt raised full-year targets: “raise our 2026 fiscal year outlook to 27.7% revenue growth, delivering approximately $11.5 billion,” while “maintain our 2026 campus revenue goal of $1.25 billion” and “raise our AI fabric goal from $3.25 billion to $3.5 billion.” Breithaupt reiterated profitability ranges: “For gross margin, we reiterate the range for the fiscal year of 62% to 64%,” and said, “Our operating margin outlook remains at approximately 46% for the fiscal year.” For Q2, Breithaupt guided “revenues of approximately $2.8 billion” and “diluted earnings per share of approximately $0.88.” Financial Results Breithaupt reported Q1 profitability and margins: “The overall gross margin ...
Earnings Call Insights: Alphatec Holdings (ATEC) Q1 2026 Management View "The business is working and is scaling." (Chairman, CEO & President Patrick Miles) "We did $192 million in Q1. This was short of our internal expectation, primarily due to a shortfall in EOS sales performance." "Surgical revenue was up 17%, mostly in line with consensus." (Chairman, CEO & President Miles) "Case is up 21%, su...
Earnings Call Insights: Alphatec Holdings (ATEC) Q1 2026 Management View "The business is working and is scaling." (Chairman, CEO & President Patrick Miles) "We did $192 million in Q1. This was short of our internal expectation, primarily due to a shortfall in EOS sales performance." "Surgical revenue was up 17%, mostly in line with consensus." (Chairman, CEO & President Miles) "Case is up 21%, surgeon is up 23%." "EOS revenue was $14 million for the quarter." (Chairman, CEO & President Miles) "We have taken steps to bolster the team in sales, downstream marketing and EOS support." "Total revenue was $192 million, up 14% year-over-year with surgical revenue of $178 million, growing 17%." (Executive VP & CFO J. Koning) "Sequentially, surgical revenue declined 6%, which was more pronounced than we have historically seen, primarily due to lower revenue per procedure contribution." "Gross margin for the quarter was 71.6%, representing over 120 basis points of improvement year-over-year." (Executive VP & CFO Koning) "Adjusted EBITDA was $21 million in the first quarter, representing 11% of revenue and growing 97% year-over-year." "We recently entered into a new Term Loan A and revolving credit facility led by JPMorgan and TD Cowen." (Executive VP & CFO Koning) "This new bank facility... extends maturities to 2031 and reduces interest expense by more than $6 million annually." Outlook "We now expect total revenue for full year 2026 of approximately $882 million, representing 15% growth year-over-year." (Executive VP & CFO Koning) "We now expect EOS revenue of approximately $77 million." "This includes surgical revenue of approximately $805 million, unchanged from our prior guidance." (Executive VP & CFO Koning) "We expect surgical case volume growth in the high teens and average revenue per case to be flat for the full year." "We continue to expect adjusted EBITDA of approximately $134 million, even with the reduced revenue expectations." (Executive VP & CFO Koning) "For ...
Earnings Call Insights: SSR Mining (SSRM) Q1 2026 Management View “In March, we announced in advance a definitive agreement to sell our interest in the Copler mine for $1.5 billion in cash... we expect it to close before the end of the third quarter of 2026,” said Executive chairman Rodney Antal, describing the deal as “a strategic repositioning... as a focused Americas-based gold and silver produ...
Earnings Call Insights: SSR Mining (SSRM) Q1 2026 Management View “In March, we announced in advance a definitive agreement to sell our interest in the Copler mine for $1.5 billion in cash... we expect it to close before the end of the third quarter of 2026,” said Executive chairman Rodney Antal, describing the deal as “a strategic repositioning... as a focused Americas-based gold and silver producer with a clear emphasis on free cash flow generation.” Antal said the post-transaction portfolio is “anchored by the Marigold and Cripple Creek and Victor operations,” and added: “We anticipate providing an update on our strategic review of Hot Maden in the coming months.” “In the first quarter, we produced 110,000 gold equivalent ounces at all-in sustaining costs of $2,433 per ounce,” said CFO Michael Sparks, adding: “We continue to expect 55% to 60% of full-year production in the second half with higher sustaining capital spend in the second and third quarters.” “Puna delivered more than $120 million in site level free cash flow in the quarter,” Sparks said, while also noting: “Following another strong quarter from CC&V, the operation has now generated approximately $325 million in mine site free cash flow since its acquisition in 2025.” Outlook “We expect it to close before the end of the third quarter of 2026,” Antal said of the Copler sale, and added: “These catalysts... will be further bolstered by the ongoing free cash flow from our Americas operations.” “We expect our ongoing free cash flow, combined with proceeds from the sale of Copler before the end of the third quarter of 2026, will further strengthen the balance sheet,” Sparks said. On capital returns, Antal said: “We suspended our capital allocation strategy with the Copler incident a few years ago... once we have clarity... we would then go back and have a look at our capital allocations and reimplementing and reinstituting it... That work is underway.” Financial Results “Our solid operational results trans...
Earnings Call Insights: Cytokinetics (CYTK) Q1 2026 Management View CEO Robert I. Blum said Cytokinetics “launched MYQORZO, our first approved medicine for the treatment of adults with symptomatic oHCM in the United States,” and added that the “initial commercial launch... is exceeding our internal expectations with net product revenue of $4.8 million in the first quarter.” CEO Blum highlighted ge...
Earnings Call Insights: Cytokinetics (CYTK) Q1 2026 Management View CEO Robert I. Blum said Cytokinetics “launched MYQORZO, our first approved medicine for the treatment of adults with symptomatic oHCM in the United States,” and added that the “initial commercial launch... is exceeding our internal expectations with net product revenue of $4.8 million in the first quarter.” CEO Blum highlighted geographic expansion, saying, “the European Commission approved MYQORZO for patients with oHCM and we're now moving quickly towards our first European commercial launch in Germany in this second quarter.” CEO Blum emphasized new clinical data, stating, “we reported positive top line results from this pivotal Phase III clinical trial of aficamten in nonobstructive HCM,” and added, “we plan to meet with regulatory authorities, including the FDA to discuss our plans for promptly submitting a supplemental NDA.” CEO Blum also pointed to regulatory timing for label expansion, saying the FDA accepted the MAPLE-HCM sNDA for filing and assigned “a PDUFA date of November 14, 2026.” Quote (EVP & CFO Sung Lee) “We are maintaining our full year 2026 financial guidance with GAAP combined R&D and SG&A expense expected to be between $830 million and $870 million.” Quote (Executive VP & Chief Commercial Officer Andrew Callos) “We plan to continue this emphasis on high-volume prescribers until we achieve over 50% new-to-brand prescription share among these HCPs, which we anticipate will occur by year-end.” Outlook The company maintained 2026 expense guidance: GAAP combined R&D and SG&A of $830 million to $870 million, including stock-based compensation of $120 million to $130 million; excluding stock-based compensation, $700 million to $750 million (EVP & CFO Sung Lee). Management did not provide product sales guidance, with EVP & CFO Lee reiterating, “As this is our first year of launching MYQORZO, we are not providing product sales guidance at this time,” and in Q1 adding, “As we have just a...
自学习 AI 的融资神话，正在告诉我们一件事——这场 AI 军备竞赛，连研究员本身都要被「卷」进去了。 1956 年，一批科学家聚在达特茅斯，第一次正式讨论「机器能否思考」。他们乐观地以为，用一个夏天就能解决这个问题。 七十年后，这个问题依然没有答案。但有一家公司，刚刚成立四个月， 就拿到了 5 亿美元融资，估值达到 40 亿美元 ——只因为它宣称，自己找到了一条路，让 AI 学会自己做研究、自己...
自学习 AI 的融资神话，正在告诉我们一件事——这场 AI 军备竞赛，连研究员本身都要被「卷」进去了。 1956 年，一批科学家聚在达特茅斯，第一次正式讨论「机器能否思考」。他们乐观地以为，用一个夏天就能解决这个问题。 七十年后，这个问题依然没有答案。但有一家公司，刚刚成立四个月， 就拿到了 5 亿美元融资，估值达到 40 亿美元 ——只因为它宣称，自己找到了一条路，让 AI 学会自己做研究、自己进化。 这家公司叫 Recursive Superintelligence。 Google 风投 GV 领投，英伟达跟投。两家公司在 AI 生态里的地位不需要赘述。它们同时出手，押注一家连产品都还没有公开的初创公司，背后的逻辑值得认真拆解。 01 「把人从循环里移走」 先说说 Recursive Superintelligence 到底在做什么。 公司由前 Salesforce 首席科学家 Richard Socher 创立，核心团队来自 Google DeepMind 和 OpenAI。这不是什么陌生的组合——过去两年，从顶级实验室出走创业的工程师和研究员，已经形成了一股明显的浪潮。 Richard Socher 的 X 个人主页，Altman 显然关注了这位人才｜图片来源：X Socher 并非硅谷常见的那种「大厂出来镀金」的创始人。他 1983 年生于德国，在斯坦福大学师从 AI 先驱 Andrew Ng 和 NLP 权威 Christopher Manning，2014 年完成博士论文，拿下当年斯坦福计算机系最佳博士论文奖。 Richard Socher 是将神经网络方法真正带入自然语言处理领域的关键人物之一——他早期关于词向量、上下文向量和提示工程的研究，直接奠定了今天 BERT、GPT 系列模型的技术基础，谷歌学术引用量已超 18 万次。 博士毕业当年，他创立了 AI 初创公司 MetaMind，两年后被 Salesforce 以战略并购的方式收入麾下。此后他以首席科学家兼执行副总裁的身份主导 Salesforce AI 战略长达数年，主导了 Einstein GPT 等企业级 AI 产品线的落地。 离开 Salesforce 后，他又在 2020 年创立了 AI 搜索引擎 You.com，2025 年完成 C 轮融资，估值达 15 亿美元。这一次，他把目光从搜...
Market Snapshot USD/INR ₹95.29 +0.2% Nifty 50 Index 24,032.80 -0.4% India 10-Year Bond Yield 7.02% +0.00 Spot Gold ($/oz) $4,633.52 +1.7% S&P 500 Futures 7,305.75 +0.3% Market data as of 08:07 AM IST, May. 6, 2026, or the previous close for Indian markets. Data is subject to provider delays. Good morning... I’m Ashutosh Joshi in Mumbai with a quick mid-week check ahead of Wednesday’s open. Local e...
Market Snapshot USD/INR ₹95.29 +0.2% Nifty 50 Index 24,032.80 -0.4% India 10-Year Bond Yield 7.02% +0.00 Spot Gold ($/oz) $4,633.52 +1.7% S&P 500 Futures 7,305.75 +0.3% Market data as of 08:07 AM IST, May. 6, 2026, or the previous close for Indian markets. Data is subject to provider delays. Good morning... I’m Ashutosh Joshi in Mumbai with a quick mid-week check ahead of Wednesday’s open. Local equities may see a bit of a recovery after Tuesday’s drop, helped by positive global cues. Asian stocks have climbed to a record and crude oil prices have declined after US President Donald Trump signaled progress toward a final agreement with Iran. Shares of Larsen & Toubro will be in focus after it reported March-quarter profit below estimates and warned that the Middle East crisis could weigh on business in coming quarters. Don’t miss our section on how analysts are viewing Prime Minister Narendra Modi’s historic election win in the West Bengal state as a catalyst for industrial stocks. Meanwhile, Bajaj Auto is set to report results later today and also consider a share buyback. In today’s newsletter, we write about: The emergence of pure-play AI bets DSP Mutual Fund’s large-cap focus A headwind for credit growth But first, let’s look at how individual investors are rerouting their money. Markets Buzz: Retail Pulls Back After peaking in 2024, individual investors’ ownership in listed companies fell to a five-year low of 9.11% at the end of March, according to Primeinfobase.com. The decline marks a retreat by the cohort that drove the rally from the depths of the pandemic in March 2020. That said, indirect ownership via mutual funds — where retail investors account for more than half of total equity assets — continued to rise, hitting a record in March. Overall, shareholding data for the January–March period show broad-based selling across investor groups, save for purchases by local institutions. Three Things to Start Your Day India’s pure-play AI bets The wait for invest...
Shares of Aehr Test Systems (NASDAQ: AEHR) soared 144.2% in April 2026, according to data from S&P Global Market Intelligence . No, that's not a typo; the semiconductor test equipment maker more than doubled in price last month. Of course, seasoned Aehr investors saw the surge as a natural extension of prevailing trends. As of this writing on May 5, for example, Aehr's stock has gained a staggerin...
Shares of Aehr Test Systems (NASDAQ: AEHR) soared 144.2% in April 2026, according to data from S&P Global Market Intelligence . No, that's not a typo; the semiconductor test equipment maker more than doubled in price last month. Of course, seasoned Aehr investors saw the surge as a natural extension of prevailing trends. As of this writing on May 5, for example, Aehr's stock has gained a staggering 1,004% in 52 weeks. Big moves have become the routine for Aehr and its investors. There were 21 market days in April. Aehr shares rose at least 5% on 7 of those days, led by a 25.7% increase on April 8. It also fell 5% or more on two occasions. I won't dive in to explain all 9 of last month's significant price swings. Let's just focus on a handful of big days, looking for repeated patterns. Continue reading